Rapid response of erythrodermic pityriasis rubra pilaris to tildrakizumab

The cases of two patients with erythrodermic pityriasis rubra pilaris that showed a rapid and virtually complete response to tildrakizumab are presented. Treatment of pityriasis rubra pilaris remains challenging and there is very little evidence about use of interleukin-23 blockers in this condition. These cases may contribute to extending the available therapeutic options, especially when a fast clearance of the lesions is needed.

Automated summary

This article presents two cases of erythrodermic pityriasis rubra pilaris that showed a rapid and almost complete response to tildrakizumab. Treatment of this condition is challenging, and there is limited evidence regarding the use of interleukin-23 blockers. These cases may contribute to expanding the available therapeutic options, particularly when fast clearance of lesions is required.